Last updated: August 5, 2026
Greer Laboratories, Inc. is a U.S. specialist in allergenic extracts used for allergy diagnosis and allergen immunotherapy. Its strongest position is in physician-administered subcutaneous immunotherapy, where product breadth, manufacturing know-how, allergen sourcing, regulatory experience and clinician distribution relationships create higher barriers than conventional generic-drug markets. Greer competes primarily with ALK-Abelló, Jubilant HollisterStier, Antigen Laboratories and other regional extract manufacturers.
Greer is part of Stallergenes Greer, a privately held allergy-immunotherapy group. Standalone revenue, product-level profitability and a complete patent schedule are not publicly reported. The company’s competitive value is therefore better assessed through product coverage, regulatory position, manufacturing infrastructure and channel access than through public-market financial metrics.
What does Greer Laboratories sell?
Greer Laboratories supplies allergenic extracts for diagnosis and immunotherapy. Its portfolio covers the main allergen categories used by U.S. allergists:
| Product category |
Representative coverage |
Primary use |
| Pollen extracts |
Trees, grasses and weeds |
Skin testing and immunotherapy |
| Mold extracts |
Multiple mold species |
Diagnosis and treatment |
| Dust-mite extracts |
Dermatophagoides species |
Diagnosis and immunotherapy |
| Animal extracts |
Cat, dog and other danders |
Diagnosis and immunotherapy |
| Insect extracts |
Insect and arthropod allergens |
Diagnostic use and selected immunotherapy |
| Venom products |
Insect venoms within the broader Stallergenes Greer portfolio |
Venom immunotherapy |
| Diagnostic reagents |
Individual and mixed allergen preparations |
Skin-prick and intradermal testing |
Greer’s core commercial model differs from that of tablet-based allergy-immunotherapy companies. Its products are generally supplied to allergy practices, hospitals, clinics and compounding or preparation operations that administer individualized treatment regimens.
The portfolio supports both diagnosis and treatment. That dual role creates recurring demand because patients commonly undergo testing before beginning immunotherapy and may receive customized treatment over several years.
How strong is Greer Laboratories’ market position?
Greer has a defensible position in U.S. allergen extracts, but it is not the only scaled supplier. The market is specialized, fragmented and operationally dependent on consistent biological raw materials.
Key competitive advantages
Greer’s main strengths are:
-
Broad allergen coverage. A large catalog reduces the need for clinics to source extracts from multiple vendors.
-
U.S. manufacturing presence. Greer’s Lenoir, North Carolina operations provide proximity to the U.S. allergy market and support domestic supply continuity.
-
Clinical workflow integration. Allergy practices value standardized ordering, predictable concentrations, lot traceability and established preparation procedures.
-
Regulatory experience. Allergenic extracts are regulated biological products, and manufacturing controls, potency testing, labeling and quality systems are important purchasing factors.
-
Parent-company platform. Stallergenes Greer adds international allergy-immunotherapy expertise, product development capability and commercial relationships outside the United States.
-
Customer switching friction. A clinic changing extract suppliers may need to revise protocols, formularies, staff training, inventory systems and patient treatment schedules.
Greer’s main weakness is that many extract products are difficult to differentiate clinically. Price, availability, concentration, packaging, documentation and service quality can weigh more heavily than conventional brand loyalty.
How does Greer compare with ALK-Abelló and Jubilant HollisterStier?
| Company |
Primary competitive position |
Relative strength |
| Greer Laboratories / Stallergenes Greer |
U.S. allergenic extracts and global allergy-immunotherapy platform |
Broad extract portfolio and established U.S. allergy channel |
| ALK-Abelló |
Allergy immunotherapy, including sublingual tablets, extracts and diagnostics |
Strong branded immunotherapy products and global scale |
| Jubilant HollisterStier |
U.S. allergy extracts, vaccines and contract manufacturing |
Manufacturing scale and diversified biologics capabilities |
| Antigen Laboratories |
Allergenic extracts and diagnostic products |
Focused U.S. specialty supplier |
| Merck |
Selected FDA-approved sublingual allergy tablets |
Branded, standardized products with narrow allergen coverage |
| Stallergenes Greer competitors in Europe |
Sublingual and subcutaneous immunotherapy |
Stronger emphasis on standardized and prescription immunotherapy products |
ALK has a stronger branded sublingual immunotherapy position. Its products include FDA-approved tablets for specific allergens, such as grass pollen and ragweed, while Greer’s traditional strength is individualized extract-based treatment. Jubilant HollisterStier presents a more diversified manufacturing competitor and may have greater scale in broader biologics production.
Greer’s strategic position is strongest where physicians need customized multi-allergen treatment rather than a single standardized tablet.
What FDA regulatory status applies to Greer allergenic extracts?
Greer’s allergenic extracts are regulated by the FDA as biological products. The regulatory framework differs by product type and degree of standardization.
The FDA distinguishes between standardized extracts, nonstandardized extracts and products used in diagnostic or therapeutic settings. Product labeling generally identifies the source material, concentration, route of administration, storage conditions, contraindications and warnings.
The U.S. allergenic-extract market does not operate like a conventional small-molecule generic market. Many extracts are not interchangeable under an automatic-substitution framework. Physicians select products based on allergen source, potency, treatment protocol and patient response.
The FDA’s regulation of allergenic extracts places practical importance on:
- Raw-material identity and quality
- Potency and consistency
- Sterility and microbial controls
- Lot release procedures
- Label accuracy
- Cold-chain and storage requirements
- Adverse-event monitoring
- Manufacturing-change controls
FDA guidance on allergenic products recognizes that biological variability and source-material characteristics affect product standardization and quality control (U.S. Food and Drug Administration, 2023).
What patents protect Greer Laboratories products?
Greer’s competitive protection is based less on publicly visible blockbuster patents and more on manufacturing capability, regulatory know-how, biological source access, quality systems and customer relationships.
Traditional allergenic extracts are generally vulnerable to limited patent exclusivity because the products rely on naturally occurring allergen sources. Patentable subject matter may include:
- Purification methods
- Allergen standardization techniques
- Stabilized formulations
- Preservative systems
- Combination compositions
- Controlled-release delivery systems
- Diagnostic platforms
- Manufacturing and extraction processes
- Sublingual or oral delivery technologies
Greer’s conventional extract products are not generally identified with the type of extensive Orange Book patent estate associated with branded small-molecule drugs. The FDA Orange Book primarily covers approved drug products and associated listed patents; it is not a comprehensive register of all intellectual property relevant to allergenic extracts.
What formulation patents may be relevant?
Formulation protection can cover extract stability, dilution systems, glycerin concentration, preservatives, buffer conditions and mixtures of allergen components. Such claims may be commercially useful but are often narrower than composition-of-matter patents for synthetic drugs.
Greer’s strongest defensibility is likely to arise where a formulation or manufacturing process produces a repeatable potency profile that is difficult for a competitor to reproduce at commercial scale. Trade secrets may be more important than published patent claims for certain extraction, blending and quality-control methods.
When does Greer lose exclusivity?
Greer does not have a single company-wide exclusivity date. Exclusivity depends on the product, regulatory pathway, patent claims and market category.
| Exclusivity type |
Relevance to Greer |
| Small-molecule patent term |
Generally limited relevance to traditional allergenic extracts |
| Biologic patent term |
Potentially relevant to certain licensed biological products |
| Orange Book listing |
Product-specific and generally not central to the traditional extract portfolio |
| Regulatory exclusivity |
Depends on FDA approval status and product category |
| Trade-secret protection |
Potentially important for extraction and standardization processes |
| Manufacturing barriers |
Important across the portfolio |
| Customer and physician relationships |
Important commercial protection |
For conventional extracts, competitive entry may occur without a formal patent challenge if a rival can produce a comparable product and satisfy FDA requirements. That makes manufacturing consistency and supply reliability central to market defense.
Are Greer Laboratories products exposed to Paragraph IV challenges?
No major public Paragraph IV campaign against Greer’s traditional allergenic-extract portfolio is a defining feature of the company’s competitive landscape.
Paragraph IV litigation is most relevant when an abbreviated new drug application relies on a branded drug with Orange Book-listed patents. Many allergenic extracts do not fit that standard model. A competitor may instead pursue its own regulatory route, challenge a specific patent outside the Orange Book, or compete through physician adoption and manufacturing capacity.
The more relevant legal risks for Greer are:
- Patent disputes over standardized allergen formulations
- Trade-secret misappropriation
- Manufacturing-process disputes
- Product-liability claims
- FDA compliance actions
- Supply and quality disputes
- Contract or distribution litigation
What patent litigation affects Greer Laboratories?
Greer has not been associated with a high-profile patent litigation campaign comparable to litigation involving major branded pharmaceutical companies. Its risk profile is operational and regulatory rather than driven by a single high-value patent cliff.
Litigation exposure can still arise from:
- Alleged infringement involving extraction or formulation processes
- Claims concerning allergen potency or product quality
- Product contamination or adverse events
- Distribution and supply agreements
- Competition over physician-specific treatment protocols
- Ownership of proprietary allergen materials or testing methods
No broad public settlement agreement is a central market event for Greer’s conventional extract business. Settlement risk is more likely to arise at the product, supplier or contract level than through a portfolio-wide patent settlement.
What generic entry risks exist for Greer Laboratories?
Generic entry risk is moderate for individual extract products but lower for the full commercial platform.
A competitor could target high-volume allergens such as dust mites, cat dander, common grasses or major tree pollens. Entry would be easier where:
- The allergen source is widely available
- The formulation is technically simple
- Clinical differentiation is limited
- Physician switching costs are low
- The product has limited standardization requirements
Entry would be harder where:
- Source material is difficult to obtain consistently
- Potency testing is complex
- The product requires extensive stability data
- Customers depend on customized mixtures
- The product is integrated into long-term treatment protocols
- A shortage would create high operational costs for clinics
The primary generic threat is therefore not an immediate mass substitution event. It is gradual price pressure, account-by-account switching and loss of share in standardized, high-volume extracts.
What manufacturing and intellectual-property barriers protect Greer?
Manufacturing barriers are more important than headline patent counts.
Biological sourcing
Allergenic extracts depend on consistent source materials. Variability in pollen, mold, mite, venom or animal-derived materials can affect potency and product quality.
Standardization
Standardized allergens require validated methods to measure and control potency. A competitor may reproduce the nominal product description but still struggle to match lot-to-lot performance.
Quality systems
The ability to produce sterile, stable and accurately labeled biological products at commercial scale is a material barrier. FDA inspection history, deviation management, batch release and documentation also affect customer confidence.
Distribution
Allergy practices require dependable supply because treatment schedules may extend over multiple years. Shortages can cause patient interruptions, protocol changes and administrative burden.
Data and know-how
Historical product-performance data, validated manufacturing parameters and physician feedback can create practical advantages that are difficult to acquire through a single patent license.
How does Greer’s commercial model affect revenue exposure?
Greer’s standalone revenue is not separately disclosed by Stallergenes Greer. The business is therefore not directly valued through a transparent public-company segment model.
Revenue drivers include:
- Number of U.S. allergy practices using Greer products
- Patient volume receiving immunotherapy
- Treatment duration
- Mix of standardized and nonstandardized extracts
- Diagnostic testing demand
- Product availability
- Pricing and reimbursement
- Growth of allergy prevalence
- Adoption of sublingual versus subcutaneous immunotherapy
The recurring nature of immunotherapy supports repeat demand. A patient may require repeated injections and periodic replacement of treatment vials. This provides a more durable demand profile than a one-time diagnostic product.
Revenue risk comes from reimbursement pressure, physician consolidation, shortages, clinic-owned compounding, competing standardized tablets and greater use of alternative allergy-treatment approaches.
What licensing deals and partnerships matter?
The most important strategic relationship is the integration of Greer into the Stallergenes Greer platform. That structure links Greer’s U.S. extract business with a broader allergy-immunotherapy portfolio.
Potential strategic advantages include:
- Cross-border product development
- Shared regulatory expertise
- Global commercialization
- Access to standardized immunotherapy technologies
- Broader physician and distributor relationships
- Manufacturing and procurement coordination
Public disclosure does not establish a major Greer-specific licensing transaction that determines the company’s U.S. extract market position. Its strategic value is more closely linked to platform integration than to a single external license.
What is the competitive outlook for Greer Laboratories?
Greer’s outlook depends on whether the allergy market remains centered on individualized injectable immunotherapy or shifts toward standardized, branded sublingual products.
Upside factors
- Rising allergy prevalence
- Greater diagnosis of allergic disease
- Persistent use of long-term immunotherapy
- Demand for multi-allergen treatment
- Physician familiarity with extract-based protocols
- Supply-chain advantages from U.S. production
- Parent-company access to global allergy assets
Downside factors
- Growth of FDA-approved sublingual tablets
- Reimbursement limits
- Physician consolidation and purchasing pressure
- Manufacturing outages
- Product standardization requirements
- Competition from ALK and Jubilant HollisterStier
- Limited patent-based pricing power
- Substitution among suppliers for common allergens
Greer has a stronger strategic position in customized extract immunotherapy than in highly standardized, single-allergen products with branded regulatory exclusivity.
Key Takeaways
- Greer Laboratories is a major U.S. specialist in allergenic extracts for diagnosis and immunotherapy.
- Its market position is supported by product breadth, U.S. manufacturing, regulatory experience and physician-channel relationships.
- ALK is the stronger competitor in branded sublingual immunotherapy, while Jubilant HollisterStier is a significant manufacturing competitor.
- Greer’s traditional portfolio is not defined by a large Orange Book patent estate or a major Paragraph IV litigation campaign.
- Manufacturing consistency, biological sourcing, potency control and supply reliability are more important than patent count.
- Generic entry risk is moderate for individual extracts but lower for the integrated platform.
- Standalone revenue and product-level financial exposure are not publicly reported.
- Stallergenes Greer’s principal strategic opportunity is to combine extract-market scale with standardized allergy-immunotherapy products.
FAQs About Greer Laboratories
Does Greer Laboratories make allergy shots?
Yes. Greer supplies allergenic extracts used by physicians to prepare subcutaneous allergy-immunotherapy treatment. Physicians determine the allergen mixture, concentration and dosing schedule.
Is Greer Laboratories owned by Stallergenes?
Greer operates within the Stallergenes Greer group. The group combines Greer’s U.S. allergenic-extract business with Stallergenes’ broader allergy-immunotherapy operations.
Does Greer Laboratories sell FDA-approved allergy tablets?
Greer’s traditional U.S. strength is allergenic extracts. FDA-approved sublingual allergy tablets are associated with other manufacturers and specific allergens, including products marketed by ALK and Merck.
Are Greer allergenic extracts interchangeable with competitor products?
They should not be assumed to be automatically interchangeable. Extract source, potency, standardization, concentration, formulation and physician protocol can differ between suppliers.
What would most threaten Greer’s market share?
The largest threats are sustained supply shortages, lower-priced extract competitors, stronger adoption of standardized sublingual products, reimbursement pressure and a major quality or regulatory event.
References
-
U.S. Food and Drug Administration. (2023). Regulatory guidance and information for allergenic products. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Approved allergenic products and biological product regulation. Center for Biologics Evaluation and Research.
-
Stallergenes Greer. (2024). Company overview and allergy immunotherapy portfolio. Stallergenes Greer.
-
DailyMed. (2024). Allergenic extract product labeling. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
